跳至主要内容
临床试验/ISRCTN70915202
ISRCTN70915202已完成未知

Comparison of efficacy and safety of postoperative treatment with loteprednol etabonate and bromfenac after phacoemulsification

Department of Ophthalmology, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical University of Lodz0 个研究点目标入组 58 人开始时间: 2018年5月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
58

研究概览

简要总结

2019 results in: https://doi.org/10.5114/ko.2019.84564 (added 07/11/2019)

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Patients with age-related cataract undergoing phacoemulsification with posterior chamber intraocular lens (PC IOL) implantation. Patients having uneventful phacoemulsification with PC IOL implantation were enrolled.
  • 2. BCVA between 0.1 and 0.5
  • 3. Cataract nuclear sclerosis in the range between II and III according to LOCS III scale
  • 4. No anti-inflammatory medication for 2 weeks prior to cataract surgery
  • 5. No allergy to loteprednol etabonate (LE) or bromfenac
  • 6. Aged 45-90 years

排除标准

  • Patients with ocular infection, glaucoma, uveitis, diabetes, pseudoexfoliation syndrome, prior ocular trauma or intraocular surgery, corneal diseases, ocular tumors, optic nerve atrophy, autoimmune diseases, endocrine, renal, neurological, psychiatric disorders were excluded from the study.

研究者

发起方
Department of Ophthalmology, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical University of Lodz

相似试验